Streetbeat News

Stock Prices

HUN

UBS has maintained its Neutral rating for Huntsman (NYSE:HUN) but lowered its price target from $25.00 to $24.00. Huntsman's shares are currently trading up 0.65% at $23.22 per share. A move to $24.00 would represent a 3.36% increase from the current share price.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 5:00 pm

IMCR

Immunocore Hldgs (NASDAQ:IMCR) has received positive analyst ratings in the last quarter, with 8 bullish and 4 somewhat bullish ratings. No bearish or indifferent ratings were observed. The company's average 12-month price target is $84.25, which has increased by 8.95% over the past month.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 5:00 pm

NTES

Over the past 5 years, NetEase (NASDAQ:NTES) has outperformed the market by 9.74% on an annualized basis, producing an average annual return of 19.04%. If an investor had bought $1000 of NTES stock 5 years ago, it would be worth $2,415.48 today.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 5:00 pm

FROG

Needham has maintained its Buy rating for JFrog (NASDAQ:FROG) but lowered its price target from $36.00 to $31.00. JFrog's shares are currently trading up 16.47% over the last 24 hours, at $26.24 per share. A move to $31.00 would account for a 18.14% increase from the current share price.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 5:00 pm

CHRW

Over the past 3 months, 9 analysts have published their opinion on C.H. Robinson Worldwide (NASDAQ:CHRW) stock. The average price target for CHRW is $84.33, a decrease of 5.51% from the previous average price target of $89.25. The ratings include 2 bullish, 2 indifferent, and 5 somewhat bearish.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 5:00 pm

RSG

Over the past 5 years, Republic Servs (NYSE:RSG) has outperformed the market by 6.64% on an annualized basis, producing an average annual return of 15.95%. If an investor had bought $1000 of RSG stock 5 years ago, it would be worth $2,106.03 today.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 5:00 pm

INCY

Goldman Sachs has maintained its Buy rating for Incyte (NASDAQ:INCY) but lowered its price target from $114.00 to $98.00. Incyte's shares are currently trading down 1.43% at $53.59 per share. A move to $98.00 would represent an 82.87% increase from the current share price.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 5:00 pm

RYN

Rayonier's stock has been upgraded from Neutral to Buy by Seaport Global, leading to a rise in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:58 pm

ADVM

Adverum Biotechnologies' stock is trading higher following Mizuho's initiation of coverage with a Buy rating and a $2 price target.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:57 pm

STZ

Trading of Constellation Brands (STZ) shares has been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:57 pm